Added to YB: 2026-02-23
Pitch date: 2026-02-21
BXN.AX [bullish]
BLS Pharmaceuticals Limited
+153.26%
current return
Author Info
No bio for this author
Company Info
BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan.
Market Cap
AUD 260.2M
Pitch Price
AUD 0.46
Price Target
N/A
Dividend
N/A
EV/EBITDA
12.26
P/E
16.87
EV/Sales
3.46
Sector
Life Sciences Tools and Services
Category
growth
>100% growth at 9x earnings... Does it last?
BXN.AX: Australian medicinal cannabis co w/ >100% CAGR since 2022. FY26 rev guide A$65-75M, EBITDA A$11.5-13.5M. Trades 8x est FY26 net income A$12.5M despite triple-digit growth. GMP facility supplies ~200 private labels; pioneered pharma gummies (25% Aus scripts). Germany contract A$6M (A$2.9M invoiced Q2), UK A$2.5M shipment. Holds Australia's first MDMA/psilocybin GMP license (14B psychedelic therapy market by 2032). Fair value A$0.076-0.087 (69-93% upside) at 13-15x P/E. Risks: lack of Germany follow-on PR, EU regulatory shifts, ruthless competition.
Read full article (5 min)